CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02587650
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:26.073646+00:00
Published At: 2020-01-27T00:00:00+00:00
Record Updated At: 2020-01-27
Results Posted At: 2020-01-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["ALK Fusion Protein Expression", "BRAF wt Allele", "Invasive Skin Melanoma", "MET Fusion Gene Positive", "NRAS wt Allele", "NTRK1 Fusion Positive", "NTRK2 Fusion Positive", "NTRK3 Fusion Positive", "RET Fusion Positive", "ROS1 Fusion Positive", "Stage III Cutaneous Melanoma", "Stage IIIA Cutaneous Melanoma", "Stage IIIB Cutaneous Melanoma", "Stage IIIC Cutaneous Melanoma", "Stage IV Cutaneous Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-01-27"
protocolSection.identificationModule.nctId: "NCT02587650"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-01-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.